A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

NCT00781443 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma

Interventions

DRUG: lebrikizumab (MILR1444A)
DRUG: placebo

Sponsor

Genentech, Inc.